Esperante Ventures

About Esperante Ventures

Esperante Ventures is a globally active life sciences corporate venture capital investor. It has to date invested EUR 500k–5m per transaction in mid-to-late stage therapeutics and commercial-stage diagnostics, in syndication with co-investors.

Highlights:

International portfolio of companies across oncology, immunology, infectious diseases, CNS, ophthalmology, hearing disorders, haematology and molecular diagnostics.

Major portfolio fundraisings: Cara Therapeutics $128m, Atox Bio $56m.

5 profitable exits; fund currently in profit. Notable outcomes: Cara Therapeutics (stock sales), Pinnacle Biologics (sale to Concordia), Thiakis (sale to Wyeth), Haemostatix (sale to Ergomed) and Versantis (sale to Genfit).

4 public listings: Cara Therapeutics (NASDAQ, whilst Director pre and post IPO, Altimmune (NASDAQ), Medicenna Therapeutics (TSX) and Silexion (NASDAQ).

Active portfolio: Acousia Therapeutics, Altimmune, Pneumagen, Silexion Therapeutics, Spiral Therapeutics, Kiyatec and Oxford Cancer Biomarkers.

Address

• Headquarters

  Siriusdreef2132 HoofddorpNoord-Holland, Netherlands